Illumina is presenting new research at the American Society of Clinical Oncology annual meeting, which began Friday in Chicago.
Highlights include data from several studies in partnership with Labcorp, a leader in comprehensive laboratory services and research and the Sarah Cannon Research Institute in Nashville demonstrating further evidence to support the use of comprehensive genomic profiling over single-gene testing.
“We’re committed to delivering impactful research to help enable genomic testing in oncology care,” said Pratheesh Sathyan, head of Oncology for the Americas region at Illumina in a news release. “The work being presented at ASCO this year, which includes research conducted with Eurofins, Labcorp and SCRI, will help advance access to precision oncology solutions for patients.”
In total, Illumina, a specialist in DNA sequencing based in San Diego, had 14 abstracts accepted to the meeting.
Illumina and Labcorp share five abstracts accepted at ASCO. The organizations have a longstanding partnership working to build evidence of the clinical impact and value of comprehensive biomarker testing for patients across different cancer types, to increase community oncology physicians’ access to the latest genomic testing.
The findings of one study indicate that the machine-learning-driven approach accurately assessed a particular characteristic of colorectal cancer and endometrial adenocarcinomas using data from comprehensive genomic and immune profiling.
Other studies focus on the use of genomic profiling over single-gene testing in cases of stage IV non-small-cell lung cancer..
